Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 17:12:676095.
doi: 10.3389/fneur.2021.676095. eCollection 2021.

Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities

Monica Margoni  1   2 , Francesca Rinaldi  1 , Paola Perini  1 , Paolo Gallo  1   3
Affiliations
Review

Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities

Monica Margoni et al. Front Neurol. .

Abstract

Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficacy and safety concerns regarding the use of these therapies in children and young adults. This review will discuss the current state of the art of POMS therapy and will focus on the newer therapies (oral and infusion disease-modifying drugs) and on those still currently under investigation.

Keywords: efficacy; first-line therapies; pediatric onset multiple sclerosis; safety; second-line therapies.

PubMed Disclaimer

Conflict of interest statement

MM reports grants and personal fees from Sanofi Genzyme, Merck Serono, Novartis and Almirall. She was awarded a MAGNIMS-ECTRIMS fellowship in 2020. FR reports grants and personal fees from Genzyme Sanofi, Merck Serono, Biogen Idec, grants from Novartis, during the conduct of the study. PP reports grants and personal fees from Merck Serono, Biogen Idec, Genzyme Sanofi, Roche, Novartis, during the conduct of the study. PG reports grants and personal fees from Merck Serono, Biogen Idec, Genzyme Sanofi, grants and personal fees from Novartis, grants from University of Padua, Department of Neurosciences DNS, grants from Veneto Region of Italy, grants from Italian Association for Multiple Sclerosis (AISM), grants from Italian Ministry of Public Health, during the conduct of the study.

References

    1. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. (2009) 66:54–9. 10.1001/archneurol.2008.505 - DOI - PubMed
    1. Waubant E, Chabas D, Okuda DT, Glenn O, Mowry E, Henry RG, et al. . Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol. (2009) 66:967–71. 10.1001/archneurol.2009.135 - DOI - PubMed
    1. Baruch NF, O'Donnell EH, Glanz BI, Benedict RH, Musallam AJ, Healy BC, et al. . Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis. Mult Scler. (2016) 22:354–61. 10.1177/1352458515588781 - DOI - PubMed
    1. Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, et al. . Natural history of multiple sclerosis with childhood onset. N Engl J Med. (2007) 356:2603–13. 10.1056/NEJMoa067597 - DOI - PubMed
    1. McKay KA, Hillert J, Manouchehrinia A. Long-term disability progression of pediatric-onset multiple sclerosis. Neurology. (2019) 92:e2764–73. 10.1212/WNL.0000000000007647 - DOI - PMC - PubMed

LinkOut - more resources